-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the evening of April 20, according to Bloomberg, I-Mab is exploring options including selling the company
How Biotech survives the winter
In the past year, from the "prosperity madness" at the beginning of the year to the "capital winter" in the second half of the year, in 2021, the biotechnology industry has experienced a roller coaster year
Since the second half of 2021, the pressure of centralized procurement has superimposed the involution of innovative drugs, which has caused the rapid cooling of the biotechnology market
After the bubble burst, Biopharm's perfect time to buy the dip
After the bubble burst, the valuation of Biotech returned to calm
Also on April 20, Regeneron acquired Checkmate for a total of $250 million, a 335% premium
refer to:
refer to:1.
1.
3.
4.
Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types.
Retrieved April 20, 2022, from https:// -and-its-investigational-immune-activator-for-potential-use-in-multiple-tumor-types-301527653.
html.
